This company is no longer active
EYES Stock Overview
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Second Sight Medical Products, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.14 |
| 52 Week High | US$12.72 |
| 52 Week Low | US$3.42 |
| Beta | 2.56 |
| 1 Month Change | -23.33% |
| 3 Month Change | -39.74% |
| 1 Year Change | -64.25% |
| 3 Year Change | -77.89% |
| 5 Year Change | -84.46% |
| Change since IPO | -99.14% |
Recent News & Updates
Second Sight, Nano Precision complete merger, renaming as Vivani Medical
Aug 30Second Sight Medical sheds ~17% after reverse stock split
Aug 19Second Sight stock rises as shareholders approve merger, name change, reverse stock split
Jul 29Second Sight stock rises ~10% on $1.1M funding from NIH for artificial vision implant trial
Jul 18Revisiting Second Sight Medical Products: The EV Is Negative And Being Short No Longer Looks Appealing
Mar 22Recent updates
Second Sight, Nano Precision complete merger, renaming as Vivani Medical
Aug 30Second Sight Medical sheds ~17% after reverse stock split
Aug 19Second Sight stock rises as shareholders approve merger, name change, reverse stock split
Jul 29Second Sight stock rises ~10% on $1.1M funding from NIH for artificial vision implant trial
Jul 18Revisiting Second Sight Medical Products: The EV Is Negative And Being Short No Longer Looks Appealing
Mar 22Shareholder Returns
| EYES | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.7% | -2.4% | -1.4% |
| 1Y | -64.2% | 8.0% | 10.5% |
Return vs Industry: EYES underperformed the US Medical Equipment industry which returned -28.4% over the past year.
Return vs Market: EYES underperformed the US Market which returned -16.7% over the past year.
Price Volatility
| EYES volatility | |
|---|---|
| EYES Average Weekly Movement | 11.3% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: EYES's share price has been volatile over the past 3 months.
Volatility Over Time: EYES's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 15 | Scott Dunbar | www.secondsight.com |
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Second Sight Medical Products, Inc. Fundamentals Summary
| EYES fundamental statistics | |
|---|---|
| Market cap | US$54.38m |
| Earnings (TTM) | -US$9.07m |
| Revenue (TTM) | n/a |
Is EYES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYES income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | -US$130.00k |
| Gross Profit | US$130.00k |
| Other Expenses | US$9.20m |
| Earnings | -US$9.07m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EYES perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/30 12:15 |
| End of Day Share Price | 2022/08/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Second Sight Medical Products, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Bauser | Colliers Securities |
| Amit Dayal | H.C. Wainwright & Co. |
| Michael Higgins | Rodman & Renshaw, LLC |